738
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Pharmacological treatment of asthma in Sweden from 2005 to 2015

, MDORCID Icon, , MD, PhDORCID Icon, , MD, PhDORCID Icon, , MD, PhDORCID Icon, , MD, PhDORCID Icon, , MD, PhDORCID Icon, , MD, PhDORCID Icon, , MD, PhDORCID Icon, , PhDORCID Icon & , MD, PhDORCID Icon show all
Pages 313-321 | Received 09 Mar 2023, Accepted 15 Oct 2023, Published online: 01 Nov 2023

References

  • 2021 GINA Main Report [Internet]. Global initiative for a-GINA. 2021. Available from: https://ginasthma.org/gina-reports/ [cited 11 November 2021].
  • Ställberg B, Lisspers K, Hasselgren M, Janson C, Johansson G, Svärdsudd K. Asthma control in primary care in Sweden: a comparison between 2001 and 2005. Prim Care Respir J. 2009;18(4):279–286. doi:10.4104/pcrj.2009.00024.
  • Backer V, Bornemann M, Knudsen D, Ommen H. Scheduled asthma management in general practice generally improve asthma control in those who attend. Respir Med. 2012;106(5):635–641. doi:10.1016/j.rmed.2012.01.005.
  • Tuomisto LE, Ilmarinen P, Niemelä O, Haanpää J, Kankaanranta T, Kankaanranta H. A 12-year prognosis of adult-onset asthma: seinäjoki Adult Asthma Study. Respir Med. 2016;117:223–229. doi:10.1016/j.rmed.2016.06.017.
  • Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, Accordini S, Almar E, Bugiani M, Carolei A, et al. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol. 2007;120(6):1360–1367. doi:10.1016/j.jaci.2007.09.019.
  • Janson C, Accordini S, Cazzoletti L, Cerveri I, Chanoine S, Corsico A, Ferreira DS, Garcia-Aymerich J, Gislason D, Nielsen R, et al. Pharmacological treatment of asthma in a cohort of adults during a 20-year period: results from the European Community Respiratory Health Survey I, II and III. ERJ Open Res. 2019;5(1):00073–2018. doi:10.1183/23120541.00073-2018.
  • Seberová E, Andersson A. Oxis®(formoterol given by Turbuhaler®) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med. 2000;94(6):607–611. doi:10.1053/rmed.2000.0788.
  • O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? Eur Respir J. 2017;50(3):1701103. doi:10.1183/13993003.01103-2017.
  • Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872. doi:10.1183/13993003.01872-2019.
  • Sundh J, Wireklint P, Hasselgren M, Montgomery S, Ställberg B, Lisspers K, Janson C. Health-related quality of life in asthma patients - A comparison of two cohorts from 2005 and 2015. Respir Med. 2017;132:154–160. doi:10.1016/j.rmed.2017.10.010.
  • Kämpe M, Lisspers K, Ställberg B, Sundh J, Montgomery S, Janson C. Determinants of uncontrolled asthma in a Swedish asthma population: cross-sectional observational study. Eur Clin Respir J. 2014;1(1):24109. doi:10.3402/ecrj.v1.24109.
  • Asthma Control Test [Internet]. Asthma control test. 2021. Available from: https://www.asthmacontroltest.com/ [cited 11 November 2021].
  • Ekström M, Nwaru BI, Wiklund F, Telg G, Janson C. Risk of rehospitalization and death in patients hospitalized due to asthma. J Allergy Clin Immunol Pract. 2021;9(5):1960–1968.e4. doi:10.1016/j.jaip.2020.12.030.
  • Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care. 2015;60(3):455–468. doi:10.4187/respcare.03200.
  • Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest. 1998;113(3):587–592. doi:10.1378/chest.113.3.587.
  • Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24(1):14009. doi:10.1038/npjpcrm.2014.9.
  • Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012;21(123):66–74. doi:10.1183/09059180.00008111.
  • Janson C, Menzies-Gow A, Nan C, Nuevo J, Papi A, Quint JK, Quirce S, Vogelmeier CF. SABINA: an overview of short-acting β2-agonist use in asthma in European countries. Adv Ther. 2020;37(3):1124–1135. doi:10.1007/s12325-020-01233-0.
  • O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zheng J, Gustafson P, Lamarca R, Puu M, Keen C, Alagappan VKT, et al. Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med. 2021;9(2):149–158. doi:10.1016/S2213-2600(20)30416-1.
  • Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, et al. Controlled trial of budesonide–formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–2030. doi:10.1056/NEJMoa1901963.
  • Usmani OS, Lavorini F, Marshall J, Dunlop WCN, Heron L, Farrington E, Dekhuijzen R. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19(1):10. doi:10.1186/s12931-017-0710-y.
  • Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, Haughney J, Henrichsen S, Hutton C, Infantino A, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017;5(4):1071–1081.e9. doi:10.1016/j.jaip.2017.01.004.
  • Sanchis J, Gich I, Pedersen S. Systematic review of ein inhaler use: has patient technique improved over time? Chest. 2016;150(2):394–406. doi:10.1016/j.chest.2016.03.041.
  • Laforest L, El Hasnaoui A, Pribil C, Ritleng C, Osman LM, Schwalm M-S, Le Jeunne P, Van Ganse E. Asthma patients’ self-reported behaviours toward inhaled corticosteroids. Respir Med. 2009;103(9):1366–1375. doi:10.1016/j.rmed.2009.03.010.
  • Ricketts HC, Cowan DC. Asthma, obesity and targeted interventions: an update. Curr Opin Allergy Clin Immunol. 2019;19(1):68–74. doi:10.1097/ACI.0000000000000494.
  • Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27(3):495–503. doi:10.1183/09031936.06.00077205.
  • Camargo CA, Boulet L-P, Sutherland ER, Busse WW, Yancey SW, Emmett AH, Ortega HG, Ferro TJ. Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast. J Asthma. 2010;47(1):76–82. doi:10.3109/02770900903338494.
  • Mohan A, Grace J, Wang BR, Lugogo N. The effects of obesity in asthma. Curr Allergy Asthma Rep. 2019;19(10):49. doi:10.1007/s11882-019-0877-z.
  • Stapleton M, Howard-Thompson A, George C, Hoover RM, Self TH. Smoking and asthma. J Am Board Fam Med. 2011;24(3):313–322. doi:10.3122/jabfm.2011.03.100180.
  • Janson C, Chinn S, Jarvis D, Burney P. Individual use of antiasthmatic drugs in the European community respiratory health survey. Eur Respir J. 1998;12(3):557–563. doi:10.1183/09031936.98.12030557.
  • Janson C, Lisspers K, Ställberg B, Johansson G, Telg G, Thuresson M, Nordahl Christensen H, Larsson K. Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR). Respir Res. 2018;19(1):168. doi:10.1186/s12931-018-0855-3.
  • Ekström M, Nwaru BI, Hasvold P, Wiklund F, Telg G, Janson C. Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden. Allergy. 2019;74(11):2181–2190. doi:10.1111/all.13874.
  • Folkhälsomyndigheten. Tobaksrökning, daglig [Internet]. Stockholm: Folkhälsomyndigheten; 2022. Available from: https://www.folkhalsomyndigheten.se/fu-tobaksrokning [cited 28 October 2022].
  • Folkhälsomyndigheten. Övervikt och fetma [Internet]. Stockholm: Folkhälsomyndigheten; 2022. Available from: https://www.folkhalsomyndigheten.se/fu-overvikt-och-fetma [cited 28 October 2022].